Elevance Health, Inc. (NYSE:ELV) Stock Has Consensus Price Target of $456.48 According to Analysts

Shares of Elevance Health, Inc. (NYSE:ELV) have been given an average recommendation of “Moderate Buy” by the twenty-two research firms that are covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $456.48.

Several research analysts recently weighed in on the stock. Barclays lifted their price objective on shares of Elevance Health from $469.00 to $472.00 and gave the stock an “overweight” rating in a research note on Thursday, October 22nd. Leerink Partners increased their price target on Elevance Health from $364.00 to $395.00 and gave the stock a “market perform” rating in a report on Friday, July 17th. Morgan Stanley upped their target price on Elevance Health from $404.00 to $449.00 and gave the company an “equal weight” rating in a report on Thursday, October 22nd. Robert W. Baird boosted their price target on shares of Elevance Health from $393.00 to $406.00 and gave the company a “neutral” rating in a research report on Thursday, October 22nd. Finally, Guggenheim boosted their price target on shares of Elevance Health from $460.00 to $485.00 and gave the company a “buy” rating in a research report on Thursday, October 22nd.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $29.02 from $27.06, and lifted forecasts for Q1 2027 and Q1 2028 to $11.73 and $12.61, respectively. An additional analyst also raised its Q2 EPS estimate, though the report did not provide the revised figure. Q2 EPS Estimate for Elevance Health Lifted by Analyst
• Neutral Sentiment: EVP Ratnakar Lavu sold 1,300 shares for $572,000, an 8.05% reduction in his holdings. He still directly owned 14,849 shares after the transaction, making the sale a limited insider-sentiment signal. SEC insider transaction filing
• Neutral Sentiment: A separate article considers what would need to be true for Elevance to be an attractive stock purchase, but the supplied article information does not state its conclusion. What Needs To Be True To Buy Elevance Health Stock?
• Negative Sentiment: Zacks Research lowered estimates for Q4 2026 EPS to $2.00 from $2.43, Q3 2027 to $6.01 from $6.70, and Q3 2028 to $7.09 from $7.75. These cuts temper the positive revisions and point to a less favorable outlook for some future quarters.

Insider Activity

In other Elevance Health news, EVP Ratnakar Lavu sold 1,300 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $440.00, for a total transaction of $572,000.00. Following the completion of the sale, the executive vice president directly owned 14,849 shares of the company’s stock, valued at approximately $6,533,560. This trade represents a 8.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Mark Kaye sold 10,584 shares of the stock in a transaction dated Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the completion of the transaction, the chief financial officer directly owned 19,919 shares of the company’s stock, valued at approximately $8,766,949.47. This trade represents a 34.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Elevance Health

Several hedge funds and other institutional investors have recently modified their holdings of ELV. BlackRock Inc. acquired a new stake in Elevance Health in the 2nd quarter worth approximately $7,344,424,000. State Street Corp raised its holdings in shares of Elevance Health by 1.3% in the second quarter. State Street Corp now owns 10,426,610 shares of the company’s stock valued at $4,032,283,000 after purchasing an additional 137,914 shares during the last quarter. Wellington Management Group LLP raised its stake in Elevance Health by 12.0% in the 2nd quarter. Wellington Management Group LLP now owns 9,213,513 shares of the company’s stock valued at $3,563,142,000 after acquiring an additional 984,976 shares during the period. First Eagle Investment Management LLC increased its holdings in Elevance Health by 1.4% in the 2nd quarter. First Eagle Investment Management LLC now owns 4,188,196 shares of the company’s stock valued at $1,619,701,000 after buying an additional 55,905 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in Elevance Health in the 2nd quarter valued at approximately $1,246,349,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Down 1.4%

Shares of ELV opened at $426.17 on Friday. Elevance Health has a one year low of $274.84 and a one year high of $450.69. The stock has a 50 day moving average price of $412.92 and a 200 day moving average price of $373.58. The stock has a market capitalization of $92.08 billion, a price-to-earnings ratio of 18.17, a PEG ratio of 1.97 and a beta of 0.63. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.47 and a current ratio of 1.47.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.71 by $2.28. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The firm had revenue of $50.44 billion for the quarter, compared to analysts’ expectations of $49.28 billion. During the same quarter in the previous year, the firm posted $6.03 EPS. The firm’s revenue for the quarter was up .7% on a year-over-year basis. Equities research analysts forecast that Elevance Health will post 29.16 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Stockholders of record on Friday, December 4th will be paid a dividend of $1.72 per share. The ex-dividend date of this dividend is Friday, December 4th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.6%. Elevance Health’s dividend payout ratio is currently 29.34%.

About Elevance Health

Elevance Health, Inc is a U.S. health benefits and services company. Formerly known as Anthem, Inc, it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans.

The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Elevance Health operates primarily in the United States, with health plans serving members across multiple states and access to broader provider networks through its Blue Cross Blue Shield affiliations.